LENZ Therapeutics, Inc. (LENZ) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $3.12 (-10.60%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Oct 27, 2025 | Matthew Caufield | H.C. Wainwright | $56.00 | +1694.9% |
| Apr 14, 2025 | Biren Amin | Piper Sandler | $51.00 | +1534.6% |
| Aug 15, 2024 | Joseph Catanzaro | Piper Sandler | $36.00 | +1053.8% |
| Aug 15, 2024 | Yigal Nochomovitz | Citigroup | $32.00 | +925.6% |
Top Analysts Covering LENZ
LENZ vs Sector & Market
| Metric | LENZ | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.33 | 2.25 | 2.41 |
| Analyst Count | 9 | 8 | 19 |
| Target Upside | +60.3% | +153002.0% | +21.5% |
| P/E Ratio | -3.51 | 3.47 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $8M | $13M | $24M | 2 |
| 2027-03-31 | $8M | $13M | $24M | 2 |
| 2027-06-30 | $10M | $16M | $28M | 2 |
| 2027-09-30 | $11M | $19M | $34M | 2 |
| 2027-12-31 | $13M | $22M | $40M | 2 |
| 2028-12-31 | $166M | $166M | $166M | 5 |
| 2029-12-31 | $175M | $281M | $442M | 2 |
| 2030-12-31 | $229M | $368M | $578M | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-1.88 | $-0.92 | $-0.45 | 4 |
| 2027-03-31 | $-1.79 | $-0.88 | $-0.42 | 2 |
| 2027-06-30 | $-1.69 | $-0.82 | $-0.40 | 2 |
| 2027-09-30 | $-1.58 | $-0.77 | $-0.37 | 2 |
| 2027-12-31 | $-1.46 | $-0.71 | $-0.35 | 2 |
| 2028-12-31 | $-2.43 | $-0.50 | $1.20 | 4 |
| 2029-12-31 | $0.99 | $1.96 | $3.41 | 2 |
| 2030-12-31 | $1.93 | $3.80 | $6.62 | 2 |
Frequently Asked Questions
What is the analyst consensus for LENZ?
The consensus among 9 analysts covering LENZ Therapeutics, Inc. (LENZ) is Buy with an average price target of $7.00.
What is the highest price target for LENZ?
The highest price target for LENZ is $56.00, set by Matthew Caufield at H.C. Wainwright on 2025-10-27.
What is the lowest price target for LENZ?
The lowest price target for LENZ is $32.00, set by Yigal Nochomovitz at Citigroup on 2024-08-15.
How many analysts cover LENZ?
9 analysts have issued ratings for LENZ Therapeutics, Inc. in the past 12 months.
Is LENZ a buy or sell right now?
Based on 9 analyst ratings, LENZ has a consensus rating of Buy (2.33/5) with a +60.3% upside to the consensus target of $7.00.
What are the earnings estimates for LENZ?
Analysts estimate LENZ will report EPS of $-0.92 for the period ending 2026-12-31, with revenue estimated at $13M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.